Skin cancer, and particularly melanoma, poses therapeutic challenges because of metastasis and limited systemic chemotherapy efficacy. The authors developed a thermosensitive hybrid hydrogel intended as a localized delivery platform to improve the therapeutic index of doxorubicin (DOX) for melanoma treatment. The platform aims to combine the advantages of a polymeric scaffold with functional nanostructures to enable controlled release and enhanced tumour drug uptake while limiting systemic exposure.
The hybrid system was built by dispersing DOX-loaded, pH-sensitive 12-2-12/SLSar catanionic vesicles into a thermosensitive poloxamer matrix identified as poloxamer F87 (poloxamer 237). The design leverages surfactant-based vesicles for drug encapsulation and the thermoresponsive character of F87 to form a gel scaffold suitable for localized administration. The source reports that the catanionic vesicles achieved high DOX encapsulation efficiency and were stably dispersed within the F87 scaffold.
Molecular-level studies documented strong polymer–surfactant interactions between F87 and the surfactant-based vesicles. Those interactions led to the formation of mixed polymer/surfactant micelles and mixed vesicular aggregates. The interactions were thermally driven and heavily dependent on the polymer-to-surfactant ratio, indicating that temperature and composition tune the assembly state and nanoscale architecture within the hydrogel.
Integration of the catanionic vesicles into the poloxamer matrix produced significant modifications in aggregate physicochemical properties, notably changes in surface charge. Despite these changes, the DOX-loaded vesicles retained high encapsulation efficiency and remained stably dispersed in the F87 scaffold. The hybridization therefore modified particle properties while preserving drug loading and colloidal stability as reported in the source.
The hybrid hydrogel was characterized in terms of rheological behavior and thermosensitivity. The source indicates that polymer–surfactant interactions were thermally driven, which influenced the formation and structural evolution of micelles and vesicles within the gel. Rheological profiling was performed as part of the comprehensive characterization to establish gelation and mechanical features relevant to local administration, though specific numeric rheological values were not reported in the abstract.
Drug-release kinetics were assessed for the hybrid hydrogel. The hybrid system exhibited controlled release kinetics, and the authors highlight potential advantages of the hydrogel formulation compared with vesicle-only systems. The scaffold-modulated release profile suggests a sustained, localized delivery of DOX from the hybrid matrix; the abstract does not provide detailed release-rate constants or numerical comparisons but emphasizes improved control versus vesicles alone.
Biocompatibility testing reported in the source indicated that the hybrid hydrogel displayed excellent biocompatibility. The hybrid system compared favorably with neat F87 hydrogels in safety assessment contexts mentioned in the abstract. Exact experimental conditions, cell types, or quantitative toxicity metrics were not included in the abstract and therefore are not specified here.
The therapeutic performance of the DOX-loaded hybrid hydrogel was evaluated in vitro using both 2D monolayer melanoma cell cultures and 3D spheroid models. The hybrid hydrogel significantly enhanced DOX internalization into melanoma cells and induced greater melanoma cell death in vitro than neat F87 hydrogels. These functional assays support the premise that embedding catanionic vesicles within a thermosensitive scaffold can improve cellular delivery and cytotoxic effect compared with polymer scaffold alone.
The reported work demonstrates a tunable and versatile strategy to integrate pH-sensitive catanionic vesicles into a thermoresponsive polymeric scaffold (poloxamer F87) for localized chemotherapy delivery. Key reported advantages include high DOX encapsulation efficiency, stable dispersion of vesicles within the scaffold, thermally driven polymer–surfactant interactions that can be modulated by composition and temperature, controlled release kinetics, excellent biocompatibility, and superior in vitro anti-melanoma performance relative to neat polymer hydrogels. The authors propose this hybrid hydrogel as a promising platform for localized melanoma therapy. Specific experimental details such as numerical rheological parameters, exact release profiles, in vitro assay conditions, and in vivo data were not reported in the abstract and therefore are not included here.